Contrasting NeuroOne Medical Technologies (NASDAQ:NMTC) & CVRx (NASDAQ:CVRX)

NeuroOne Medical Technologies (NASDAQ:NMTC) and CVRx (NASDAQ:CVRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Profitability

This table compares NeuroOne Medical Technologies and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%
CVRx	-84.93%	-152.35%	-50.93%

Volatility & Risk

NeuroOne Medical Technologies has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, CVRx has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Insider & Institutional Ownership

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 16.6% of CVRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares NeuroOne Medical Technologies and CVRx”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10 million	0.84	-$3.61 million	($0.95)	-1.18
CVRx	$56.65 million	0.74	-$53.31 million	($1.98)	-0.80

NeuroOne Medical Technologies has higher earnings, but lower revenue than CVRx. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for NeuroOne Medical Technologies and CVRx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1	1	3	0	2.40
CVRx	1	3	2	0	2.17

NeuroOne Medical Technologies currently has a consensus target price of $7.33, suggesting a potential upside of 554.76%. CVRx has a consensus target price of $4.30, suggesting a potential upside of 172.15%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher possible upside, equities research analysts plainly believe NeuroOne Medical Technologies is more favorable than CVRx.

Summary

NeuroOne Medical Technologies beats CVRx on 8 of the 13 factors compared between the two stocks.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.